Timothy D Murtha1, Beatrice C Lupsa2, Sachin Majumdar2, Dhanpat Jain3, Ronald R Salem4. 1. Department of Surgery, Section of Surgical Oncology, Yale School of Medicine, Yale University, 333 Cedar Street, FMB 130, P.O. Box 208062, New Haven, CT, 06520-8062, USA. 2. Department of Medicine: Endocrinology, Yale School of Medicine, Yale University, New Haven, CT, USA. 3. Department of Pathology: GI and Liver Pathology, Yale School of Medicine, Yale University, New Haven, CT, USA. 4. Department of Surgery, Section of Surgical Oncology, Yale School of Medicine, Yale University, 333 Cedar Street, FMB 130, P.O. Box 208062, New Haven, CT, 06520-8062, USA. ronald.salem@yale.edu.
Abstract
BACKGROUND: Pancreatic neuroendocrine tumors (PNETs) are a heterogeneous group of islet cell-derived neoplasms with a propensity toward hormone production. Among PNETs, proinsulin-secreting tumors (proinsulinomas) are exceedingly rare. The objective of this study is to collect and summarize the existing literature to provide a comprehensive evaluation of this uncommon disease. METHODS: A systematic review was performed to characterize the clinicopathologic features of proinsulinoma. Using the electronic biomedical databases PubMed, Ovid Medline, and Embase, 316 publications were screened for relevance of which 14 were selected. We also present two patients with proinsulinoma treated at Yale New Haven Hospital. RESULTS: Of the 16 patients included in the study, the mean age was 56.8 and there was a 2:1 female predominance. The majority of patients presented with symptomatic hypoglycemia with normal or low insulin levels. Median tumor diameter was 1.2 cm and 80% were located in the body and tail of the pancreas. Following resection, most patients had normalization of hormonal levels without recurrence (75%; 12/16). CONCLUSION: Proinsulinomas are rare pancreatic neuroendocrine tumors that have the potential to cause hypoglycemia. While insulinomas and proinsulin-secreting tumors have many physiologic parallels, these cases illustrate several key distinctions in their diagnosis and management.
BACKGROUND:Pancreatic neuroendocrine tumors (PNETs) are a heterogeneous group of islet cell-derived neoplasms with a propensity toward hormone production. Among PNETs, proinsulin-secreting tumors (proinsulinomas) are exceedingly rare. The objective of this study is to collect and summarize the existing literature to provide a comprehensive evaluation of this uncommon disease. METHODS: A systematic review was performed to characterize the clinicopathologic features of proinsulinoma. Using the electronic biomedical databases PubMed, Ovid Medline, and Embase, 316 publications were screened for relevance of which 14 were selected. We also present two patients with proinsulinoma treated at Yale New Haven Hospital. RESULTS: Of the 16 patients included in the study, the mean age was 56.8 and there was a 2:1 female predominance. The majority of patients presented with symptomatic hypoglycemia with normal or low insulin levels. Median tumor diameter was 1.2 cm and 80% were located in the body and tail of the pancreas. Following resection, most patients had normalization of hormonal levels without recurrence (75%; 12/16). CONCLUSION:Proinsulinomas are rare pancreatic neuroendocrine tumors that have the potential to cause hypoglycemia. While insulinomas and proinsulin-secreting tumors have many physiologic parallels, these cases illustrate several key distinctions in their diagnosis and management.
Authors: Francisco J Gómez-Pérez; Daniel Cuevas-Ramos; Paloma Almeda Valdés; Carlos A Aguilar-Salinas; Roopa Mehta; Juan A Rull Journal: Endocr Pract Date: 2010 Jul-Aug Impact factor: 3.443
Authors: Steven N Hochwald; Sui Zee; Kevin C Conlon; Roberto Colleoni; Otway Louie; Murray F Brennan; David S Klimstra Journal: J Clin Oncol Date: 2002-06-01 Impact factor: 44.544
Authors: Kana Fujikura; Bobak Heydari; Yin Ge; Kyoichi Kaneko; Shuaib Abdullah; William S Harris; Michael Jerosch-Herold; Raymond Y Kwong Journal: Am J Cardiol Date: 2019-12-09 Impact factor: 2.778
Authors: Seong Keat Cheah; David Halsall; Peter Barker; John Grant; Abraham Mathews; Shyam Seshadri; Singhan Krishnan Journal: Endocrinol Diabetes Metab Case Rep Date: 2018-09-24